Related Experiment Video
Updated: Jan 2, 2026
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
16.4K
Current and potential treatments for primary biliary cholangitis
1Liver Institute Northwest, Seattle, WA, USA.
The Lancet. Gastroenterology & Hepatology
|December 7, 2019
Summary
Many primary biliary cholangitis patients need better treatments beyond ursodeoxycholic acid and obeticholic acid. New therapies targeting immune dysfunction and bile acid pathways show promise for improving patient outcomes.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Primary biliary cholangitis (PBC) often shows incomplete response to ursodeoxycholic acid (UDCA).
- Obeticholic acid (OCA) is a second-line option, but many patients still require additional therapies.
- There is a significant unmet need for novel treatments to prevent disease progression and liver failure in PBC.
Purpose of the Study:
- To review current and emerging therapeutic strategies for primary biliary cholangitis.
- To discuss the potential of agents targeting immunological and metabolic pathways in PBC.
- To inform the development of personalized treatment regimens for PBC patients.
Main Methods:
- Review of existing literature on PBC treatments.
- Analysis of drugs modulating immune responses and bile acid homeostasis.
- Discussion of emerging therapies targeting specific pathogenic pathways.
Main Results:
- Budesonide, ciclosporin, and rituximab show potential in modifying PBC.
- Bezafibrate demonstrates benefits in bile acid homeostasis and liver enzyme levels.
- Ongoing research focuses on therapies targeting bile acid homeostasis, immune dysfunction, and fibrogenesis.
Conclusions:
- Novel therapeutic targets for PBC include immune modulation, bile acid homeostasis, and fibrogenesis.
- Emerging therapies offer potential for improved clinical outcomes in non-responsive PBC patients.
- Understanding treatment mechanisms is crucial for tailoring future therapeutic strategies.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
268
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
268
01:17Chronic Bowel Disorders: Introduction
705
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
705
01:29Inflammatory Bowel Disease IV: Pharmacological Management
413
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
413
01:30Acute Pancreatitis II: Clinical Manifestations and Management
665
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
665
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
408
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
408
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K